Intestinal Perforation in Colorectal Cancers Treated with Bevacizumab (Avastin®)
نویسندگان
چکیده
منابع مشابه
Intestinal perforation in colorectal cancers treated with bevacizumab (Avastin).
Bevacizumab is a monoclonal antibody that targets vascular endothelial growth factor (VEGF), and it has shown promise as a clinical agent against metastatic colorectal cancer, and particularly in combination with chemotherapy. Bowel perforation is a known risk that's associated with bevacizumab use, but the etiology is unknown. Here we report on two cases of metastatic colorectal cancer in whic...
متن کاملGastrointestinal Perforation in Patients with Metastatic Colorectal Cancer treated with Bevacizumab (Avastin) Three Cases Report
approved by the U.S. Food and Drug Administration in February 2004 and the European Medicines Agency in January 2005 for use in metastatic colorectal cancer (mCRC). In a phase III clinical trial it was shown to improve survival and progression-free survival and an increased response rate as compared to a chemotherapy (IFL) regimen containing bolus fluorouracil (5-FU), leucovorin (LV), and irino...
متن کامل[Coat's disease treated with bevacizumab (Avastin)].
CASE REPORT We report a case of Coats' disease in a 10-year-old-girl who presented with a profound visual deficit, exudative retinal detachment, vascular telangiectasias and subretinal lipid, who underwent treatment with an intravitreal injection of bevacizumab (AVASTIN(TM)). Serial examinations documented an involutional response with a reduction of the subretinal fluid, exudates and macular t...
متن کاملIntestinal perforation in a patient with paroxysmal nocturnal hemoglobinuria
Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder that manifests with hemolytic anemia, thrombosis, and peripheral blood cytopenias.Acute abdominal pain is one of the PNH clinical manifestations due to venous thrombosis of intra-abdominal sites including hepatic, portal, mesenteric, and splenic veins.Eculizumaband allogeneic bone marrow transplantation (BMT) arethe only w...
متن کاملPharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits
PURPOSE To describe the pharmacokinetics of intravitreal bevacizumab (Avastin®) in rabbits. METHODS The right eye of 20 rabbits was injected intravitreally with 1.25 mg/0.05 mL bevacizumab. Both eyes of four rabbits each time were enucleated at days 1, 3, 8, 15, and 29. Bevacizumab concentrations were measured in serum, aqueous humor, and vitreous. RESULTS Maximum vitreous (406.25 μg/mL) an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Cancer Research and Treatment
سال: 2008
ISSN: 1598-2998
DOI: 10.4143/crt.2008.40.1.33